MediGene to research ovarian cancer antibody

By Elaine Rigoli

Tampa, Fla., July 6 - MediGene AG and the German Cancer Research Center have formed a collaboration for the therapeutic development of monoclonal antibodies against the ovarian cancer protein L1.

After the two-year collaboration ends, MediGene said it will have the option to acquire a worldwide license on the application of anti-L1 antibodies in antitumor therapy.

The L1 protein highly specifically occurs on the cell surfaces of malignant ovarian and endometrial tumors (ovarian and uterine cancer), whereas it is not found in the respective healthy tissue or benign tumors.

For this reason, MediGene said this protein is especially suited as a new tumor marker in diagnostics and therapy.

MediGene is a biotechnology company located in Martinsried, Germany, and San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.